

RECEIVED  
CENTRAL FAX CENTER

APR 12 2007

**HAMRE, SCHUMANN,  
MUELLER & LARSON, P.C.**  
AN INTERNATIONAL INTELLECTUAL PROPERTY LAW FIRM

FAX TRANSMISSION

April 12, 2007

TO: Mail Stop:  
Examiner:  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FROM: Douglas P. Mueller

OUR REF: 08279.1209USWO

TELEPHONE: (612) 455.3800

Total pages, including cover letter:

4


PTO FAX NUMBER: 571.273.8300

If all pages are NOT received, please call us at 612.455.3800 or fax us at 612.455.3801.

Title of Document: PTO/SB/96; PTO/SB/80

Applicant: Akiyama et al.  
Serial No.: 10/531069  
App. Filed: April 11, 2005  
Group Art No.: 1615

Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By:   
Name: Douglas P. Mueller  
Reg. No.: 30,300

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Ratlynn Wilhelm

  
Signature04.12.07  
Date225 SOUTH SIXTH STREET • SUITE 2650 • MINNEAPOLIS • MN 55402  
TEL. 612.455.3800 • FAX 612.455.3801  
WWW.HSML.COM • MAIL@HSML.COM

PTO/SB/88 (09-08)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: TAKEDA PHARMACEUTICAL COMPANY LIMITEDApplication No./Patent No.: 10/531069 Filed/Issue Date: April 11, 2005**RECEIVED  
CENTRAL FAX CENTER**

Entitled:

**APR 12 2007**TAKEDA PHARMACEUTICAL COMPANY LIMITED, a CORPORATION

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %)

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: INVENTORS To: TAKEDA PHARMACEUTICAL COMPANY LIMITED

The document was recorded in the United States Patent and Trademark Office at  
Reel 018935, Frame 0879, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_


The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

  
\_\_\_\_\_  
Signature

\_\_\_\_\_  
APRIL 12, 2007

\_\_\_\_\_  
DOUGLAS P. MUELLER  
Printed or Typed Name

\_\_\_\_\_  
Date

\_\_\_\_\_  
ATTORNEY FOR APPLICANT  
Title

\_\_\_\_\_  
812.455.3804

\_\_\_\_\_  
Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED  
CENTRAL FAX CENTER

APR 12 2007

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

RECEIVED  
CENTRAL FAX CENTER

APR 12 2007

PTO/SB/80

**POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO**

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ The practitioners associated with the Customer Number: 52835

as attorneys or agents to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with patent applications identified below:

Serial Number	Filing Date	Inventor(s)	Docket No.
10/530,785	April 8, 2005	Nomomura et al.	08279.1208USWO
10/531,069	April 11, 2005	Akiyama et al.	08279.1209USWO
10/535,268	March 21, 2006	Kubo et al.	08279.1210USWO
10/574,048	May 12, 2006	Kubo et al.	08279.1211USWO
11/515,639	September 5, 2006	Hashimoto et al.	20039.0014USD1
10/475,990	March 2, 2004	Naito et al.	20039.0015USWO
10/498,461	May 26, 2004	Oda et al.	20039.0016USWO
10/475,815	February 5, 2004	Naito et al.	20039.0017USWO

Patent Number	Issued Date	Inventor(s)	Docket No.
7,169,799	January 30, 2007	Hashimoto et al.	20039.0014USWO

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:


☒ The address associated with Customer Number: 52835

Assignor: Takeda Pharmaceutical Company Limited is a corporation organized and existing under and by virtue of the laws of the Japan, and having an office and place of business at:

1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi  
Osaka 541-0845 Japan

**Signature of Assignee of Record**

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee.

Signature		Date: March 26, 2007
Name	Hiroshi AKIMOTO, Ph.D.	
Title	Managing Director, Member of the Board	

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.